Print
Email
Biovail Corp. (BVF) filed Quarterly Report for the period ended 2011-09-30.
Biovail Corp. has a market cap of $1.64 billion; its shares were traded at around $0 with a P/E ratio of 26.8. The dividend yield of Biovail Corp. stocks is 13.7%.
This is the annual revenues and earnings per share of BVF over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of BVF.
Highlight of Business Operations:
Total revenues increased $392.3 million, or 188%, to $600.6 million in the third quarter of 2011, compared with $208.3 million in the third quarter of 2010, and increased $1,108.3 million, or 166%, to $1,775.0 million in the first nine months of 2011, compared with $666.7 million in the first nine months of 2010, primarily due to:Net income increased $248.7 million to $40.8 million (diluted earnings per share of $0.13) in the third quarter of 2011, compared with net loss of $207.9 million (diluted loss per share of $1.27) in the third quarter of 2010, and increased $280.8 million to $103.7 million (diluted earnings per share of $0.32) in the first nine months of 2011, compared with net loss of $177.1 million (diluted loss per share of $1.11) in the first nine months of 2010, reflecting the following factors:
Total revenues increased $392.3 million, or 188%, to $600.6 million in the third quarter of 2011, compared with $208.3 million in the third quarter of 2010, and increased $1,108.3 million, or 166%, to $1,775.0 million in the first nine months of 2011, compared with $666.7 million in the first nine months of 2010. A substantial portion of these increases was due to the incremental revenues of Valeant, PharmaSwiss and Sanitas of $278.6 million, $59.7 million and $17.0 million, respectively, in the third quarter of 2011, and $846.2 million, $141.3 million and $17.0 million, respectively, in the first nine months of 2011, while the remaining increase was mainly attributable to the effect of the following factors:
Total segment profit increased $111.2 million, or 155%, to $183.0 million in the third quarter of 2011, compared with $71.8 million in the third quarter of 2010, and increased $262.6 million, or 95%, to $539.5 million in the first nine months of 2011, compared with $276.9 million in the first nine months of 2010. A substantial portion of these increases was due to the inclusion of operations of Valeant, net of realized synergies from the Merger, and PharmaSwiss, while the remaining increase was mainly attributable to the effect of the following factors:
Cost of goods sold, which excludes the amortization of intangible assets described separately below under "— Amortization of Intangible Assets", increased $100.4 million, or 162%, to $162.5 million in the third quarter of 2011, compared with $62.1 million in the third quarter of 2010, and increased $316.8 million, or 171%, to $501.7 million in the first nine months of 2011, compared with $184.9 million in the first nine months of 2010. The percentage increase in cost of goods sold in the third quarter of 2011 was lower than the corresponding 188% increase in total revenues in the third quarter of 2011, and the percentage increase in cost of goods sold in the first nine months of 2011 was higher than the corresponding 166% increase in total revenues, primarily due to:
Subscribe RSS
